AN2 Market Capitalization from 2010 to 2025

ANTX Stock  USD 1.27  0.02  1.60%   
AN2 Therapeutics Market Cap yearly trend continues to be fairly stable with very little volatility. Market Cap will likely drop to about 245.5 M in 2025.
Check AN2 Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among AN2 Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 84.1 M, Interest Expense of 620.7 K or Selling General Administrative of 17.8 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 4.24. AN2 financial statements analysis is a perfect complement when working with AN2 Therapeutics Valuation or Volatility modules.
  
Check out the analysis of AN2 Therapeutics Correlation against competitors.
For more information on how to buy AN2 Stock please use our How to Invest in AN2 Therapeutics guide.

Latest AN2 Therapeutics' Market Capitalization Growth Pattern

Below is the plot of the Market Cap of AN2 Therapeutics over the last few years. It is AN2 Therapeutics' Market Cap historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in AN2 Therapeutics' overall financial position and show how it may be relating to other accounts over time.
ViewLast Reported 37.95 M10 Years Trend
Pretty Stable
   Market Cap   
       Timeline  

AN2 Market Capitalization Regression Statistics

Arithmetic Mean300,767,238
Geometric Mean294,423,064
Coefficient Of Variation22.67
Mean Deviation39,655,161
Median288,592,704
Standard Deviation68,190,419
Sample Variance4649.9T
Range298.7M
R-Value0.25
Mean Square Error4661.4T
R-Squared0.06
Significance0.34
Slope3,633,636
Total Sum of Squares69749T

AN2 Market Capitalization History

2025245.5 M
2024435.2 M
2023483.6 M
2022184.9 M

About AN2 Therapeutics Financial Statements

AN2 Therapeutics investors use historical fundamental indicators, such as AN2 Therapeutics' Market Capitalization, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in AN2 Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases. The company was incorporated in 2017 and is headquartered in Menlo Park, California. An2 Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 25 people.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for AN2 Stock Analysis

When running AN2 Therapeutics' price analysis, check to measure AN2 Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy AN2 Therapeutics is operating at the current time. Most of AN2 Therapeutics' value examination focuses on studying past and present price action to predict the probability of AN2 Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move AN2 Therapeutics' price. Additionally, you may evaluate how the addition of AN2 Therapeutics to your portfolios can decrease your overall portfolio volatility.